New antibody cocktail targets tough tumors
NCT ID NCT05229497
First seen Mar 21, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study tests two experimental drugs (AK112 and AK117) given together to people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink or control the tumors. About 154 adults aged 18 to 75 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.